The IASLC 2024 Pan-Africa Conference on Lung Cancer (PACLC), January 31 - February 1, 2025 in Accra, Ghana, is the first multidisciplinary lung cancer conference in Sub-Saharan Africa. This conference is an exclusive gathering for healthcare providers dedicated to improving lung cancer care in the region. Delegates will gain comprehensive knowledge on lung cancer prevention and screening, the latest updates in pathology, genomics, targeted therapy, and immunotherapy, and diagnostic excellence with a focus on differentiating lung cancer from tuberculosis. The event will also address the unique challenges of managing lung cancer in resource-constrained settings and foster future collaborations to enhance care.

This activity is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer including medical oncologists, thoracic surgeons, radiation oncologists, radiologists, pathologists, advanced practice nurses and physician assistants.

Upon completion of this activity, the participants should be able to: 

• Gain comprehensive knowledge on lung cancer prevention and screening. 
• Analyze diagnostic excellence with a focus on differentiating lung cancer from tuberculosis.
• Review the latest updates in pathology, genomics, targeted therapy, and immunotherapy.  
• Address the unique challenges of managing lung cancer in resource-constrained settings. 
• Foster future collaborations to enhance lung cancer care in Sub-Saharan Africa.

• Alex Adjei, MD, PhD, Chief, Enterprise Cancer Institute, Director, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA
• Jane Sandra Afriyie-Mensah, MD, Senior Pulmonologist & Researcher, University of Ghana and Korle Bu Teaching Hospital, Ghana
• Souheil Boubia, MD, University Hospital IBN Roch Casablanca, Morocco
• Mansoor Saleh, MD, Professor and Chair, Department of Haematology/Oncology, The Aga Khan University Hospital, Kenya
• Chukwumere Nwogu, MD, PhD, Professor of Thoracic Surgery, Roswell Park Comprehensive CAncer Center, Buffalo, NY, USA; and CEO,Lakeshore Cancer Center, Lagos, Nigeria
• Raymond Osarogiagbon, MBBS, FASCO, Baptist CAncer Center-Memphis Thoacic Multidisciplinary Care, Memphis, TN, USA
• Ronwyn Van Eeden, MBBCh, Medical Oncologist, Dr. Ronwyn Van Eeden Oncology, Johannesburg, South Africa

The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

If you need any assistance with this activity, please email: education@iaslc.org.